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Radiotherapy is the most successful nonsurgical treatment for nasopharyngeal carcinoma (NCP).
Although NPCs initially respond well to a full course of radiation, recurrence and metastasis are fre-
quent. In this study, we found that down-regulated c-MYB expression was associated with increased
radiation resistance and DNA damage repair ability. Interestingly, c-MYB was over-expressed in can-
cer tissues but not in the adjacent tissues. Down-regulation of c-MYB expression inhibited cell pro-
liferation, and led to cell cycle arrest at the M phase in NPC cells. Luciferase and chromatin
immunoprecipitation assays demonstrated that c-MYB transactivated miR-143 through direct bind-
ing to its promoter. Based on these results, c-MYB might target miR-143 in order to regulate stem
cell properties, cell growth, apoptosis, and DNA damage repair.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The c-MYB protein is a transcription factor [1] that plays a key
role in the cell cycle regulation, proliferation, and differentiation of
hematopoietic cells. High expression levels of c-MYB were ﬁrst
found in immature bone marrow hematopoietic cells and thymo-
cytes, and subsequently in the neuroectodermal gastrointestinal
epithelium and vascular smooth muscle cells. Recent studies have
also shown that abnormal expression of c-MYB can lead to colon,
breast, and gastro-esophageal cancer [2]. c-MYB can activate cru-
cial target genes related to cancer progression and metastasis,
including Sox-2, Bcl-2, Bax, and c-MYC [3]. Studies have indicated
that the transcription factor MYB governs intestinal stem cell gene
expression through the Wnt signaling pathway and thereby affects
tumor cell self-renewal [4]. MicroRNAs (miRNAs) are an extensive
class of 18–24-nucleotide long non-coding RNAs that regulate gene
expression at the post-transcriptional level [5]. They have been
reported to play an important role in the development, prolifera-tion, and differentiation of various types of cells [6–8]. MiRNAs
have also been linked to radio- and chemoresistance [9]. Recent
studies have indicated that the expression of miRNA-143 was sig-
niﬁcantly down-regulated in several human neoplasms including
colon, ovarian, esophageal, and bladder cancer [10,11]. Noguchi
et al. reported that miR-143 inhibits cell growth through down-
regulation of the translational expression level of ERK5 and AKT
[12]. In addition, Lin et al. showed that miR-143 targeted the RAS
oncogene, contributing to inhibition of tumor invasion and metas-
tasis [13]. Radiation therapy is the main treatment for nasopharyn-
geal carcinoma (NPC). However, patients with an early diagnosis
who receive radiation therapy nonetheless experience frequent
recurrence. During the past in the last decades, evidence has been
provided that the cancer stem cell (CSC) content and intrinsic
radiosensitivity can affect their radiocurability potential. In this
study, we detected the level of expression of c-MYB and miR-143
in normal nasopharyngeal and NPC tissues. Furthermore, we ana-
lyzed the relationships between the expression levels of c-MYB
and the clinicopathological parameters of NPC patients. We also
studied the effects of c-MYB on cell growth and its radiation-resis-
tant mechanism in NPC cells, with the aim of determining a novel
potential therapeutic approach for the treatment of NPC.
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2.1. Cell culture
Human NPC cell lines, c666-1, 5-8F, CNE1 and CNE2, were
maintained in RPMI 1640 culture (Life Technologies, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS), 100 units/
mL penicillin G and 100 lg/mL streptomycin. Np69 cells were
maintained in Keratinocyte-SFM culture (GIBCO, USA). All the cells
were maintained in a humidiﬁed 5% CO2 incubator at 37 C, all the
cell lines we used without EBV infection.
2.2. Tumorsphere formation assay
Tumorsphere culture was performed as described previously
[20]. For sphere formation assay, 500–800 single cells/well are
seeded in serum-free DMEM-F12 supplemented with 1  B27 (Life
Technologies), 20 ng/mL epidermal growth factor, and 20 ng/mL
basic ﬁbroblast growth factor in ultralow attachment (ULA) plate.
Medium was replenished every 4 days and spheres counted within
2 weeks. For secondary (2) sphere formation assay, the 1 spheres
were trypsinized into single cells and reseeded (500 cells/well) in
the ULA plate. The 2 spheres were counted in 10 days. The 2
spheres >50 lm were counted by microscope.
2.3. Radiation assay
The NPC cells after c-MYB inhibitor or co-treatment with c-MYB
inhibitor and miR-143 were irradiated with 8 Gy of 160 kV X-rays
using RS 2000 X-ray Biological Irradiator (Rad Source Technologies,
USA) at a dose rate of 1 Gy/min. and co-treated w cells to X-ray to
determine their radiation sensitivity differences. Cells were col-
lected for Western blot, cell cycle and apoptosis assay after irradi-
ated 12 h. Experiments were run in triplicate.
2.4. Aldeﬂuor assay
The Aldeﬂuor assay was carried out according to manufacturer’s
guidelines. Brieﬂy, 1  106 single cells obtained from cell cultures
were suspended in 1 ml Aldeﬂuor assay buffer containing an ALDH
substrate, 5 lL Aldeﬂuor reagent, and were incubated for 45 min at
37 C with continuous mixing. Subsequently, ﬂow cytometry was
used to measure the ALDH-positive cell population.
2.5. Quantitative real-time PCR
Total RNA was extracted using the TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and the resulting mRNAwas reverse transcribed
into cDNA using 5 PrimeScript RT Master Mix (TaKaRa Bio Group,
Dalian, China). The reaction conducted at 37 C for 15 min and
85 C for 5 s, according to the manufacturer’s protocol. Quantita-
tive PCR (qPCR) was performed using 2 SYBR Premix Ex Taq
(TaKaRa Bio Group, Dalian, China) with a 7300 ABI real-time PCR
System (Applied Biosystems, Foster City, CA, USA) under the fol-
lowing conditions: 95 C for 30 s, 95 C for 5 s and 60 C for 31 s
for 40 cycles. The relative mRNA levels were analyzed by the
2(44Ct) method with GAPDH as an internal control. Primers used
for real-time PCR were: c-MYB forward, 50-GCCAATTATCTCCC-
GAATCGA-30 and c-MYB reverse, 50-ACCAACGTTTCGGACCGTA-30
(Table S1).
The details of patients and tissue samples, immunohistochemis-
try (IHC), antibodies, Western blotting and immunoﬂuorescence,
clonogenic survival assays, cell proliferation, quantitative lucifer-
ase assay, cell cycle and apoptosis assay are in Doc S1.2.6. Statistical analysis
All experiments were repeated at least three times. The data
was expressed as the mean value ± standard deviation (S.D.). The
ﬁndings were considered signiﬁcant at a P value of <0.05. All statis-
tical analyses were performed by the v5.0 GraphPad Prism Pro-
gram, (GraphPad Software Inc., SanDiego, CA, USA).
3. Results
3.1. The expression of MiR-143 and c-MYB in human tumor cell lines
and clinical specimens
c-MYB was previously found to regulate the cell cycle, prolifer-
ation, and differentiation of hematopoietic cells [1]. To verify the
role of c-MYB in NPC in vivo, a panel of human tumor cell lines
was ﬁrst analyzed to quantitate the expression level of c-MYB. In
order to link miR-143 with NPC, we performed q-RT-PCR in 4
NPC cell lines and found that the miR-143 expression levels were
lower in NPC undifferentiated C666-1, low-differentiated CNE-2,
and 5-8F cell lines compared to the highly differentiated CNE-1
and immortalized non-tumorigenic NP69 cell lines, which’ were
negatively correlated with c-MYB expression (Fig. 1A and B). We
further examined the expression levels of miR-143 and c-MYB in
specimens obtained from 105 cases of nasopharyngeal carcinoma
and adjacent tissues, 31 cases of normal nasopharyngeal epithelial.
Consistent with the data obtained from tumor cell lines, the aver-
age expression level of miR-143 was signiﬁcantly lower in malig-
nant tumor cells, whereas c-MYB expression was increased in
these cells compared to non-tumorigenic NP69 cells (Fig. 1C and
D).
3.2. Immunohistochemical analysis of c-MYB and miR-143 expression
in NPC tissues
We measured the expression levels and subcellular localization
of c-MYB and miR-143 protein in 105 archived parafﬁn-embedded
NPC samples using immunohistochemical staining. The relation-
ship between clinicopathological characteristics and c-MYB and
miR-143 expression levels in individuals with NPC are summarized
in Table 1. c-MYB and miR-143 expression in the nucleus was sig-
niﬁcantly related to the T classiﬁcation (T1–T2 vs. T3–T4; P = 0.027
and P = 0.009, respectively), N classiﬁcation (N0–N1 vs. N2–N3;
P = 0.020 and P = 0.01, respectively), distant metastasis (P = 0.000
and P = 0.007, respectively), and clinical stage (I–II vs. III–IV;
P = 0.000 and P = 0.000, respectively), whereas it was not associ-
ated with the patients’ gender, age, or histological subtype
(P > 0.05). These results indicated that tumor invasion beyond the
muscularis propria, positive lymph node metastasis, positive lym-
phatic invasion, and progressive stage were all associated with
abnormal expression of c-MYB. In primary tumors, high expression
of c-MYB was signiﬁcantly associated with decreased miR-143
expression (Fig. 2A, Spearman correlation coefﬁcient, 0.2851;
P = 0.000).
To further demonstrate the value of c-MYB expression in pre-
dicting survival of NPC patients, as shown in Fig. 2B and C, Kap-
lan–Meier curves and log-rank survival tests suggested that miR-
143 and c-MYB expression in NPC patients was associated with
survival time, with signiﬁcantly increased overall survival of
patients with high miR-143 expression in their NPC lesions com-
pared to those with low miR-143 expression (P < 0.0001). In con-
trast, the overall survival of patients with high expression of c-
MYB in their NPC lesions was signiﬁcantly reduced compared to
those with low c-MYB expression (P < 0.0001).
Fig. 1. MiR-143 was down-regulated and c-MYB was up-regulated in nasopharyngeal carcinoma (NPC) cells and clinical specimens. Expression of miR-143 (A) and c-MYB (B)
in NPC cells. Bars represent mean values ± S.D. of three independent experiments; ⁄P < 0.05, ⁄⁄P < 0.05. The relative expression levels of miR-143 (C) and c-MYB (D) in NPC
tissues and matched normal tissues as detected by q-RT-PCR (⁄P < 0.05).
Table 1
Correlation between c-Myb expression levels of tumors and clinical variables.
Variables n c-Myb (n, %) miR-143 (n, %)
Low High P Low High P
Gender
Male 56 24 (42.9) 32 (57.1) 30 (53.6) 26 (46.4)
Female 49 23 (46.9) 26 (53.1) 0.675 26 (53.1) 23 (46.9) 0.958
Age (years)
>38 75 34(45.3) 41(54.7) 39(52.0) 36(48.0)
638 30 13(43.3) 17(56.7) 0.852 17(56.7) 13(43.3) 0.665
Histological subtype
DNKC 83 40 (48.2) 43 (51.8) 41 (49.4) 42 (50.6)
UDC 22 7 (31.8) 15 (68.2) 0.170 15 (68.2) 7 (31.8) 0.116
T classiﬁcation
T1–T2 50 28 (56.0) 22 (44.0) 20 (40.0) 30 (60.0)
T3–T4 55 19 (34.5) 36 (65.5) 0.027⁄ 36 (65.5) 19 (34.5) 0.009⁄
N classiﬁcation
N0–N1 63 34 (54.0) 29 (46.0) 40 (63.5) 23 (36.5)
N2–N3 42 13 (31.0) 29 (69.0) 0.020⁄ 16 (38.1) 26 (61.9) 0.011⁄
Distant metastasis
No 56 36 (64.3) 20 (35.7) 23 (41.1) 33 (58.9)
Yes 49 11 (22.4) 38 (77.6) 0.000⁄ 33 (67.3) 16 (32.7) 0.007⁄
Clinical stage
I–II 53 40 (75.5) 13 (24.5) 15 (28.3) 38 (71.1)
III–IV 52 7 (44.8) 45 (55.2) 0.000⁄ 41 (78.8) 11 (21.2) 0.000⁄
DNKC, differentiated non-keratinizing carcinoma; UDC, undifferentiatied carcinoma; T, tumor size; N, lymph node (⁄P < 0.05).
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cells
The results described above clearly demonstrated that c-MYB is
highly expressed in NPC tissues and cells. In order to further clarifythe role of c-MYB in NPC cells, we used c-MYB inhibitors (c-MYBi)
to inhibit the expression of c-MYB in 5-8F and CNE2 cells. The
inhibitory effect of c-MYBi was detected using Western blot anal-
ysis (Fig. 3A). Because the effects of c-MYB1-#2 inhibitor were
most obvious, we used this inhibitor in subsequent experiments.
Fig. 2. Kaplan–Meier analysis of survival rate of patients with respect to c-MYB and miR-143 expression. (A) Correlation analysis of expression levels of c-MYB and miR-143
with patient survival. (B, C) The inﬂuence of c-MYB (B) and miR-143 (C) expression on the prognosis of patients with nasopharyngeal carcinoma.
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were transfected with either normal control (NC) or c-MYBi-#2.
Results of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay showed that down-regulated c-MYB expres-
sion in cMYBi-#2-treated cells inhibited the growth of 5-8F cells by
2-fold (P < 0.05) and that CNE2 cells by 2.1-fold (P < 0.05) com-
pared to control cells (Fig. 3B). Following the observation of
c-MYBi-mediated growth inhibition, we examined its effect on col-
ony formation rate and the cell-cycle distribution (Fig. 3C and D).
The colony formation rate was signiﬁcantly decreased in c-MYBi-
treated cells when compared with NC MYB-expressing cells
(P < 0.05). Furthermore, the proportion of cells at the G2/M phase
was signiﬁcantly reduced in the 5-8F and CNE2 cells after transfec-
tion with c-MYBi (P < 0.05). Next, we examined the expression of
cell cycle-related proteins. Previous research has indicated that
cyclin B1 is the main regulatory element of the cell cycle’s G2
restriction point [14]. In addition, it is known that cyclin D1 is
the main regulatory element of the G1/S phase [15]. As shown in
Fig. 3E, after inhibition of c-MYB expression by c-MYBi, cyclin B1
protein expression was down-regulated, whereas cyclin D1 protein
expression was up-regulated.
3.4. c-MYB directly regulates miR-143 expression
Sequence analysis of the miR-143 promoter revealed potential
c-MYB binding sites (MBSs) within 2.0 kb of the transcriptional
start site. These sites were designated as 1881 MBS-A, 1717
MBS-B, and 628 MBS-C, based on their respective upstream posi-
tions with reference to the transcriptional start site (Fig. 4A). To
determine whether endogenous c-MYB could physically associate
with these conserved MBSs within the miR-143 promoter, we used
a chromatin immunoprecipitation (ChIP) analysis in CNE2 cells for
all the putative MBSs. As shown in Fig. 4B, ChIPs were carried out
with anti-c-MYB antibody and precipitated signiﬁcant amounts of
DNA product when compared with the control reactions used. The
control experiments included in these ChIP assays were performed
under identical conditions except for the use of anti-IgG instead of
the c-MYB antibodies. The ChIP results revealed that c-MYB was
most signiﬁcantly bound to MBS-C within the miR-143 promoter.
Knockdown of c-MYB diminished the amount of MBS-C DNA that
could be immunoprecipitated by the c-MYB antibody (Fig. 4D).This suggested that c-MYB is directly and speciﬁcally associated
with this promoter region.
To examine the potential physiological signiﬁcance of c-MYB
protein binding to the miR-143 promoter, miR-143 expression lev-
els were examined in CNE2 cells after being treated with small
hairpin (shRNA) targeted to the endogenous c-MYB mRNA. Results
of q-RT-PCR showed that c-MYB mRNA expression was reduced 48
hours after CNE2 cells were transfected with the c-MYB-targeted
shRNA. Delivery of these shRNAs into CNE2 cells also resulted in
an increase in miR-143 levels (Fig. 4C and E).
3.5. c-MYB promotes the NPC CSCs through down-regulation of miR-
143
To elucidate whether c-MYB regulation of miR-143 could also
inﬂuence CSC properties, we down-regulated c-MYB expression
using c-MYBi and co-expressed miR-143 mimics in 5-8F and
CNE2 cells. NC-transfected cells were used as control groups. As
shown in Fig. 5A, Western blot analysis was carried out for vimen-
tin, E-cadherin, SOX-2, and NANOG. This allowed us to evaluate
speciﬁc CSC characteristics of the 5-8F and CNE2 cell lines. The
results indicated that the epithelial markers of E-cadherin and
vimentin were increased and decreased, respectively. The stem cell
surface markers SOX-2 and NANOG were decreased in 5-8F and
CNE2 cells. To examine whether CSCs were affected after c-MYBi
and miR-143 treatment, we detected CSCs using Aldeﬂuor analyses
and CD44 immuno label (Fig. 5B; Supplementary Fig. 1). When
compared with the control, c-MYBi reduced by 1.1% and 1.3% in
ALDH-positive population, and 2.9% and 3.3% in CD44-positive
population, while cells co-expressing c-MYBi and miR-143 showed
a reduction in the ALDH-positive population by 0.3% and 0.6%, and
CD44-positive population by 0.6% and 0.3% for 5-8F and CNE2 cells,
respectively. We next inhibited c-MYB in the 5-8F and CNE2 cells
over-expressing miR-143 and found that the number and size of
tumorspheres formed were signiﬁcantly reduced compared to
those in cells treated with only c-MYBi (Fig. 5C). In order to deter-
mine the impact of c-MYB-regulated miR-143 expression on stem
cell makers, an immunoﬂuorescence analysis was performed,
which revealed that SOX-2 was strongly and equally expressed
in the nuclei of 5-8F and CNE2 cells. SOX-2 was expressed at low
levels in the nuclei of co-transfected cells (Fig. 5D). The expression
Fig. 3. Low expression of c-MYB inhibits cell growth in cancer cells. (A) Western blot analysis of c-MYB expression in 5-8F and CNE2 cells. GAPDH was used as the loading
control. (B) Statistical plots of three independent cell growth assays. 5-8F and CNE2 cells were transfected and harvested at different times, as indicated. (C) Representative
images of the colony formation assay of c-MYBi-infected 5-8F and CNE2 cells. Colonies were evaluated and values are reported as the ratio between c-MYB-targeted shRNA-
infected cells and vector-infected cells. Bars represent the mean ± S.D. of three independent experiments; ⁄P < 0.05, ⁄⁄P < 0.05. (D) Representative histograms for cell-cycle
distributions of 5-8F and CNE2 cells transfected with c-MYBi. (E) Western blot analysis of cyclin B1 and cyclin D1 expression in 5-8F and CNE2 cells. GAPDH was used as the
loading control.
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samples using immunohistochemical staining. The results showed
that c-MYB was highly expressed in the nucleus. NANOG and SOX-
2 were observed both in the cytoplasm and nucleus of cancer cells
(Fig. 5E).
3.6. Induction of radiation resistance in NPC cells by c-MYB regulation
of the miR-143 promoter
Many studies have reported the importance of CSC-induced
transdifferentiation on radiosensitivity. We observed that c-MYB
negatively regulated the expression of miR-143, which reduced
the enrichment of CSCs. In order to elucidate the relationship
between c-MYB and radiosensitivity, we compared the radiation
response of NPC cells with different levels of c-MYB. When 5-8F
and CNE2 cells were seeded at increasing densities and exposed
to ionizing radiation, cells with down-regulated expression of c-
MYB were found to be signiﬁcantly less resistant to radiation than
vector-transfected cells (Fig. 6A). We also found up-regulation ofcleaved caspase-3 and cleaved PARP following 8-Gy irradiation
treatment via Western blotting in NPC cell lines in the control
group. Conversely, in cells with down-regulated expression of c-
MYB, the expression of cleaved caspase-3 and cleaved PARP did
not increase. This indicated that c-MYB might have induced
reduced apoptosis by preventing caspase-3 and PARP cleavage
(Fig. 6B).
To conﬁrm that radiation treatment induces apoptosis, we
transfected c-MYBi, miR-143, or vector control into the 5-8F and
CNE2 cells, and the cells were double-stained with Annexin V/7-
AAD and subjected to ﬂow cytometry analysis. The results revealed
that the percentage of apoptotic 5-8F and CNE2 cells increased
from 6.85% to 11.66% and from 7.00% to 11.79% in 5-8F and
CNE2 cells, respectively, following 8-Gy irradiation for 24 h
(Fig. 6C).
To determine whether c-MYB and miR-143 affected double-
strand break (DSB) repair, we measured the extent of unrepaired
DNA damage. This was performed using a single-cell neutral
comet assay in 5-8F and CNE2 cells transfected with c-MYBi or
Fig. 4. c-MYB directly regulates miR-143 expression. (A) Diagram of the c-MYB-binding sites within 2000 bp of the transcriptional start site for miR-143. (B) ChIP assay using
antibodies against c-MYB on CNE2 cells. Levels of c-MYB-binding sites (A–C) immunoprecipitated by anti-c-MYB are shown. Results represent three independent
experiments, mean + S.D.; ⁄P < 0.05. (C) Expression levels of miR-143 after CNE2 cells were transfected with c-MYB shRNA for 48 h. (D) ChIP assay using antibodies against c-
MYB on CNE2 cells with silenced c-MYB expression. Levels of c-MYB-binding site C bound by c-MYB. The results are the mean values + S.D. of three independent experiments,
⁄P < 0.05. (E) c-MYB shRNA up-regulated miR-143 expression in CNE2 cells. The results are the mean values + S.D. of three independent determinations, ⁄P < 0.05.
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quantiﬁes the extent of unrepaired DNA damage. After 8-Gy radia-
tion exposure, the frequency of comet tails was higher (P < 0.05) in
5-8F and CNE2 cells co-expressing c-MYBi and miR-143 as
compared to those only expressing c-MYBi (P < 0.05, Fig. 6D).
4. Discussion
NPC therapy often fails because patients develop high resis-
tance to chemotherapy and radiotherapy. Therapeutic resistance
is likely due to multiple factors. Some studies found that a highly
tumorigenic subpopulation of stem cell-like NPC cells are highly
resistant to radiation and chemotherapies. Understanding the
molecular mechanisms underlying this NPC phenotype will be cru-
cial for developing a therapeutic approach to overcome NPC radio-
resistance. In this study, the expression levels of c-MYB and miR-
143 were found to be up- and down-regulated, respectively, in
NPC compared to normal tissue. Furthermore, down-regulated
expression of c-MYB signiﬁcantly inhibited NPC cell proliferation.
We also found that c-MYB directly regulated the expression of
miR-143. Interestingly, miR-143 regulation by c-MYB was critical
for the CSC phenotype and radiosensitivity of NPCs.
c-MYB has been associated with cell proliferation and differen-
tiation regulation in leukemia and colon cancer. The proliferation
of malignant cells is often accompanied by high levels of c-MYB
expression, whereas benign differentiation of tumor cells requires
down-regulation of c-MYB [2,16]. Furthermore, we examined the
different degrees of malignancy in human NPC specimens. c-MYBand the stem cell surface markers SOX-2 and NANOG were widely
expressed at all levels of NPC malignancy. This phenomenon was
also veriﬁed in NPC cell lines. We compared the levels of c-MYB
expression in NPC patient samples and found a signiﬁcant associa-
tion with distant metastasis. Furthermore, c-MYB expression was
signiﬁcantly higher in patients at clinical stage III–IV compared
to those at stage I–II (P < 0. 05). Similarly, a previous study showed
that 82% of adenoid cystic carcinomas of the head and neck stained
positive for MYB protein as compared with non-adenoid cystic car-
cinoma neoplasms. This was an indication that MYB immunostain-
ing might be useful for the diagnosis of adenoid cystic carcinoma
[17]. Kim et al. examined c-MYB expression in malignant tissue
specimens from 10 patients with head and neck squamous cell car-
cinoma (HNSCC) [18]. Over-expression of shRNA targeting MYB in
HNSCC cells inhibited in vitro cell proliferation. Furthermore, the
expression of growth factors such as insulin-like growth factor
(IGF)-I, -II, -1R, and vascular endothelial growth factor (VEGF)
inhibited Akt/PKB pathway activation and enhanced induction of
apoptosis. Previous studies have shown that the c-MYB protein
induced speciﬁc effects on the cell cycle at G1/S and on regulation
of T cell proliferation. In particular, c-MYB expression is relatively
high in cells that are in the late G1 phase entering the S phase [19].
In this study, we found that over-expression of c-MYB signiﬁcantly
stimulated the growth of NPC cells through a shortened G1 phase
and an extended S/G2 phase. These results suggest that c-MYB
might play a role in the cellular growth, development, and prolifer-
ation of NPC. MiR-143 is known to be down-regulated in NPC. Fur-
thermore, studies have shown that miR-143 is down-regulated in
Fig. 5. c-MYB promotes NPC cancer stem cell markers through upregulation of miR-143. (A) Western blot analysis of vimentin, E-cadherin, SOX-2, and NANOG expression in
5-8F and CNE2 cells. GAPDH was used as the loading control. (B) Left panel: Aldeﬂuor assay of the proportion of ALDH+ cells among total number of 5-8F and CNE2 cells. Right
panel: Percentage of ALDH+ cells. Results were expressed as the mean ± S.D. of three separate trials; ⁄P < 0.05. (C) Left panel: Representative images of irradiated (8 Gy) 5-8F
and CNE2 cells that were seeded in tumorsphere culture medium at 1000 cells/well for 7 days. Right panel: Data shown represent the average sphere count from a
representative experiment performed in triplicate wells. Data represent the mean value ± S.D.; n = 3, ⁄P < 0.05. (D) Immunoﬂuorescence detection of SOX-2 expression in 5-8F
and CNE2 cells. (E) Immunohistochemical staining of c-MYB, NANOG, and SOX-2 in nasopharyngeal carcinoma tissues (magniﬁcation 400 for all images).
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sive mucinous phenotype in colorectal cancer [21,22]. In a mouse
colorectal carcinoma xenograft study, overexpression of miR-143impaired tumor growth by induction of apoptosis and inhibition
of proliferation [23]. Other miRNAs are also considered to have
tumor suppressor activity and are also down-regulated in cancers,
Fig. 6. c-MYB regulation of the miR-143 promoter in nasopharyngeal carcinoma cells results in radiation resistance. (A) Clonogenic survival of 5-8F and CNE2 cells seeded at
different densities. (B) Representative Western blot analysis of caspase 3, PARP, cleaved caspase 3, and cleaved PARP in 5-8F and CNE2 cells. GAPDH was used as the loading
control. (C) Left panel: The Annexin V/7AAD double-staining method was used to detect the percentage of apoptosis after c-MYB over-expression and radiation exposure of c-
MYB/miR-143-transfected 5-8F and CNE2 cells. Right panel: Percentage of apoptosis cells. Results were expressed as the mean ± S.D. of three separate trials; ⁄P < 0.05. (D)
Representative images of the comet assay used to detect DNA double-strand breaks (DSBs) in 5-8F and CNE2 cells due to radiation. Histogram of the comet assay data. The
results are the mean value ± S.D. of three independent experiments; ⁄P < 0.05, ⁄⁄P < 0.05. Induction of DSBs by c-MYB and/or miR-143 in the radiation-exposed 5-8F and CNE2
cells was assessed using a neutral comet assay. (E) Representative Western blot analysis of c-H2AX in 5-8F and CNE2 cells. GAPDH was used as the loading control.
562 W. Wang et al. / FEBS Letters 589 (2015) 555–564including let-7, miR-15, miR-16, miR-17-5p, miR-29, miR-34, miR-
124a, miR-127, miR-145, and miR-181 [24]. To validate the direct
association between c-MYB andmiR-143 promoters, we performed
ChIP analyses in CNE2 cells using an antibody speciﬁc to c-MYB.
The ChIP results revealed that c-MYB most signiﬁcantly bound to
MBS-C within the miR-143 promoter. Next, we showed that
down-regulation of c-MYB expression in CNE2 cells effectively pro-moted miR-143 expression at the mRNA level. This suggested a
potential inverse relationship between miR-143 and c-MYB in
NPC. Clinically, the main reason for treatment failure is disease
recurrence and metastasis. Recent research has focused on recur-
rence in CSCs, a small subpopulation of tumor cells that are
tumor-initiating and drive the production of cancer cells. Progress
in this ﬁeld has highlighted the necessity of targeting these cells as
W. Wang et al. / FEBS Letters 589 (2015) 555–564 563they strongly determine the response to treatment [25]. An impor-
tant relationship between c-MYB and CSCs was recently reported,
with important implications for breast cancer cell invasion and
metastasis [26]. In this study, the down-regulation of c-MYB in
human NPC cells (5-8F and CNE2) reduced CSC enrichment and
caused a loss of epithelial and gain of mesenchymal markers, indi-
cating its role in EMT [27]. c-MYB is also involved in liver CSC self-
renewal, potentially via modulation of miR-150 that interacts with
the 30 untranslated region of c-MYB mRNA, as overexpression of
miR-150 down-regulates c-MYB protein levels [28]. Peng et al.
examined bone metastasis of prostate cancer and found that
down-regulation of miR-143 and -145 was negatively correlated
with bone metastasis [29]. We used c-MYB shRNA to transfect 5-
8F and CNE2 cells, which resulted in increased expression of
miR-143. As a result the signiﬁcantly inhibited ALDH+ cell popula-
tion, 5-8F and CNE2 cells showed a reduced number of tumor-
spheres. These ﬁndings indicate that miR-143 and c-MYB
expression could be associated with metastasis of NPC, and suggest
that they might also play an important role in the metastasis and
regulation of CSCs. Radiation therapy plays an important role in
NPC treatment. However, recurrence is observed in most patients,
and some patients even develop radioresistance that might limit
any further treatment. It is well known that CSCs play an important
role in tumor progression and recurrence [25,30]. Furthermore,
CSCs are reported to be related to the development of radioresis-
tance in many cancers [31]. Studies have demonstrated that deliv-
ering high doses of radiation to breast cancer cells induces the cells
to exhibit the classic hallmarks of CSCs, which ultimately promote
increased cancer cell recurrence [32]. Our study of gradient-dose
irradiation showed high c-MYB expression in cells with enhanced
radiation resistance. Ionizing radiation leads to cell death through
the production of unrepairable DNA DSBs. A hallmark of DNA DSB
recognition and repair is histone H2A phosphorylation, which is
thought to mark speciﬁc sites of DNA damage [33]. By detecting
DNA damage in individual cells (via analysis of histone H2AX phos-
phorylation), we found that c-MYBi and miR-143 co-expression in
5-8F and CNE2 cells could lead to DNA damage repair and recovery
of radiation sensitivity. In summary, our ﬁndings suggest that c-
MYB might play an important role in the metastasis of NPC. By fur-
ther focusing on the role of miR-143 in regulating NPC stem cells,
regulation of radiation resistance of NPC cells might be achieved.
Understanding the molecular mechanisms that potentiate radiore-
sistance is critical for the development of new radiotherapeutic
strategies to overcome this carcinoma.
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